A recent article in the Los Angeles Times discusses industry pushback against proposed federal legislation that would allow the manufacturers of generic pharmaceutical drugs the ability to “inform people about all known health risks” associated with various drugs produced. The Generic Pharmaceutical Association was quoted saying that the new regulations “would create ‘dangerous confusion’ and
February 2014
Ethicon and its Faulty Pelvic Mesh Devices: Destroying Valentine’s Day…and Implicating Documents
Part I: Destroying Valentine’s Day
Two weeks ago was Valentine’s Day— a holiday that is supposed to be full of romance and heartfelt encounters with those you love. For many lucky people, Valentine’s Day was exactly that this year. Countless couples across the country could be seen on dates, filling restaurants, theaters, and dance-halls to…
Verdict in Favor of Ethicon: No Big Win in the Grand Scheme of Things
Over the course of the past several days, Ethicon, a Johnson & Johnson company, has crowed over the fact that it “prevailed” in a lawsuit regarding the pelvic mesh devices it manufactured and promoted. At first glance, the media headlines regarding Ethicon’s recent “triumph” are confusing, and might even make it seem like Ethicon has…
AndroGel and False Claims of Low Testosterone: Dying to be a Man…Literally
The alpha-male. It’s a term traditionally used to describe an individual male mammal that is considered to hold the highest social standing in his community. Typically, an animal rises to alpha-male status by exhibiting signs of masculinity, confidence, and aggression to his peers. In acknowledgement of the alpha’s strength and leadership role, other members of…
2014 – Serious ailment likely the result of surgical robots
An article published in the January-February, 2014 edition of Female pelvic medicine and reconstructive surgery titled “Pneumomediastinum after robotic sacrocolpopexy.” reviews a case of pneumomediastinum in a woman who underwent robot-assisted surgery for the repair of posthysterectomy prolapse. The team writes “Pneumomediastinum is a rare but potential complication of laparoscopy that is related…
2012 – Actos raises risk for bladder cancer 15-40%
In 2012, an article titled “Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis.” was published by IN Colmers et al. in Canadian Medical Association Journal investigating the relationship between Actos and bladder cancer. Thiazolidinediones are a class of diabetes drugs including pioglitazone, the chemical…
2013 – 21% complication rate with robot-assisted surgery
In the December, 2013 edition of European Urology, a team of researchers led by RK Kumar published the results of a study titled “Robot-assisted Partial Nephrectomy in Patients with Baseline Chronic Kidney Disease: A Multi-institutional Propensity Score-Matched Analysis.” that aimed to evaluate the relative safety of robot-assisted nephrectomy, as compared with a…
2014 – Longer operating time, more pain with surgical robots
A recent article published in the January 2014 edition of Obstetrics and Gynecology titled “Robotic compared with laparoscopic sacrocolpopexy: a randomized controlled trial.” lives up to its title and compares the safety and efficacy of robot-assisted to traditional sacrocolpoplexy.
The team, led by JT Anger, writes “Laparoscopic and robotic sacrocolpopexy are widely used…
2014 – High rate of complications seen with robot-assisted surgery
In 2014, an article by AM Coker et al. titled “Outcomes of robotic-assisted transhiatal esophagectomy for esophageal cancer after neoadjuvant chemoradiation.” in Journal of Laparoendoscopic & Advanced Surgical Techniques aimed to “determine if [robotic-assisted transhiatal esophagectomy (RATE)] could be performed safely with good outcomes for esophageal cancer in a more recent series of…
2012 – Long term Actos use doubles risk for bladder cancer
In 2012, an article by L. Azoulay et al. titled “The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study.” aimed to “determine if the use of pioglitazone is associated with an increased risk of incident bladder cancer in people with type 2 diabetes.” …